Background The first-in-class antibody-drug conjugate TAK-264 (formerly MLN0264) consists of an antibody targeting guanylyl cyclase C (GCC) conjugated to monomethyl auristatin E …

2013年5月20日 · Background: MLN0264, an investigational ADC that targets GCC, consists of a fully human monoclonal antibody conjugated to the cytotoxic microtubule disrupting agent …

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C Invest …

2013年11月1日 · The transmembrane cell surface receptor GCC is expressed by ∼95% of primary and metastatic colorectal cancer (mCRC) tumors. MLN0264 has shown selective …

2017年2月11日 · The investigational ADC TAK-264 (formerly MLN0264), which we have evaluated in this study, consists of a human mAb that specifically targets guanylyl cyclase C …

The investigational antibody-drug conjugate MLN0264 consists of a fully human monoclonal antibody targeting GCC linked to monomethyl auristatin E (MMAE) via a protease-cleavable …

MLN0264 在表达鸟苷酸环化酶 C 的晚期胃肠道恶性肿瘤成年患者中进行的一项开放标签、剂量递增、第 1 阶段、首次人体研究. 这是一项开放标签、多中心、剂量递增、MLN0264 对表达鸟 …

2016年10月15日 · Purpose: To assess the safety, tolerability, and preliminary antitumor activity of the investigational anti-guanylyl cyclase C (GCC) antibody-drug conjugate TAK-264 (formerly …

2017年5月19日 · TAK-264 (formerly MLN0264) consists of a human monoclonal anti-GCC antibody conjugated to monomethyl auristatin E (MMAE) via a protease cleavable peptide linker .

2014年5月20日 · Background: This first-in-human study (NCT01577758) assessed the safety and tolerability, dose limiting toxicities (DLTs), maximum tolerated dose (MTD), pharmacokinetics, …